Results 221 to 230 of about 1,442,988 (353)

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma [PDF]

, 2009
Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien‐Hsing Chang   +4 more
openalex   +1 more source

European Principles of Nursing Care for Persons With Inherited Bleeding Disorders

Haemophilia, EarlyView.
ABSTRACT Introduction A nurse is one of the core members of the multidisciplinary haemophilia team. However, what people with inherited bleeding disorders (PwBD) can expect from them has not yet been formally defined. Aim This project, initiated by the EAHAD Nurses Committee, aimed to establish Principles of Nursing Care (PoNC) for PwBD to promote high‐
Nanda Uitslager, Mary Kavanagh, Maj Birkedal, Linda Myrin‐Westesson   +3 more
wiley   +1 more source

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy [PDF]

, 2010
Robert M. Sharkey, Edmund A. Rossi, William J. McBride, Chien‐Hsing Chang, David M. Goldenberg   +4 more
openalex   +1 more source

A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies

Internal Medicine Journal, EarlyView.
Abstract T‐cell re‐directional therapies, including chimeric antigen receptor (CAR)‐T cell and bispecific antibodies (BsA), have transformed the treatment landscape to benefit patients with multiple myeloma. A number of these novel therapies has been approved internationally, with CAR‐T therapy recently approved in Australia.
P. Joy Ho, Eric W. Li
wiley   +1 more source

Sequencing bispecific antibodies and CAR T cells for FL. [PDF]

Hematology Am Soc Hematol Educ Program
Russler-Germain DA, Bartlett NL.
europepmc   +1 more source

A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells [PDF]

, 2010
Edmund A. Rossi, Diane L. Rossi, Rhona Stein, David M. Goldenberg, Chien‐Hsing Chang   +4 more
openalex   +1 more source

Research Advice for Early Career Transplant Infectious Disease Clinicians

Transplant Infectious Disease, EarlyView.
ABSTRACT As part of an ongoing series of social media discussions, the Transplant Infectious Diseases Early Career Network hosted an open forum for the transplant infectious disease community to discuss the development of research careers for junior faculty. Topics discussed included opportunities for research, identifying potential research questions,
Rebecca N. Kumar, Michael J. Scolarici, Chelsea Gorsline, Lara Danziger‐Isakov, John Baddley, Courtney E. Harris   +5 more
wiley   +1 more source

Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies. [PDF]

Biomol Ther (Seoul)
Choi SM, Lee JH, Ko S, Hong SS, Jin HE.
europepmc   +1 more source

Functional analysis of bispecific antibody (EpCAMxCD3)‐mediated T‐lymphocyte and cancer cell interaction by single‐cell force spectroscopy [PDF]

, 2010
Sabrina Hoffmann, Guido H. Wabnitz, Yvonne Samstag, Gerhard Moldenhauer, Thomas Ludwig   +4 more
openalex   +1 more source

Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial

International Journal of Cancer, Volume 156, Issue 11, Page 2158-2168, 1 June 2025.
What's new? Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi), has shown promise in treating patients with B‐cell malignancies following treatment with covalent BTKis. However, potential geographic and ethnic differences in patient response to pirtobrutinib remain to be clarified.
Yanyan Liu, Ningjing Lin, Shuhua Yi, Huiqiang Huang, Ye Guo, Qingyuan Zhang, Haiyan Yang, Huilai Zhang, Liling Zhang, Ru Feng, Yijiao Qian, Jiankun Zhu, Yuqin Song, Jun Zhu   +13 more
wiley   +1 more source